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Abstract. The serpin superfamily of serine protease
inhibitors is one of the most ubiquitous and successful
classes of inhibitors in the living world. Their unique
mechanism of suicide inhibition has led to much
research and several important discoveries. They
function via rapid incorporation of a reactive centre
loop (RCL) within a β-sheet following the former’s
proteolysis by the target protease: the serpin thus
achieves a conformation which is more stable than the
native form. Through this conformational change, the
target protease structure is distorted and its function
disrupted. Alpha-1-antitrypsin (AAT) has often been
studied as an archetype for the serpin superfamily,
and is discussed in more detail in this review. Of
particular interest are the mutant variants of AAT,
which have a tendency to polymerise, and thus offer
insights into some mechanisms of serpin polymerisation.
Keywords Serpin, RCL, glycosaminoglycan, AAT,
loop-sheet polymerisation, serpinopathy
1 The Serpin Superfamily
1.1 Introduction
Serpins are a diverse superfamily of proteins, most of
which are serine protease inhibitors - hence their name
(Huntington 2011; Khan et al. 2011). The size and
RCL: reactive centre loop
AAT: alpha-1-antitrypsin
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ubiquity of this superfamily is testament to the evo-
lutionary success of the serpin structure and function.
There are more than 1500 serpin-like genes identified in
a wide spectrum of organisms (Law et al. 2006). While
the distribution may be vast, it is not even: all mul-
ticellular eukaryotes possess serpins (Law et al. 2006),
whereas they are found only infrequently in prokaryotes
(Irving et al. 2002b). Similarly, serpin structure dif-
fers between kingdoms of life. In fact, ’classical’ serpins
are found in higher eukaryotes and viruses, but not in
prokaryotes (Irving et al. 2002b).
Some serpins not only inhibit protease inhibitors, but
also cysteine proteases (Irving et al. 2002a) such as
the caspases (Lockett et al. 2012), cathepsins (Fluhr et
al. 2011; Higgins et al. 2010), and calpains (Luke et
al. 2007). Still other serpins have no inhibitory activity,
such as chicken ovalbumin (Huntington 2011), and corti-
costeroid binding globulin (CBG) and thyroxine binding
globulin (TBG) in humans (Carrell et al. 2011). HSP47
is another non-inhibitory human serpin, which serves as
a collagen-specific molecular chaperone (Nagata, 2003),
and has potential as a target for Alzheimer’s disease
therapy (Bianchi et al. 2011).
So far, 36 serpins have been identified in humans, 27
of which are inhibitory (Law et al. 2006) as shown in
Table 1. They serve functions including regulation of in-
flammation (Horn et al. 2012; Huntington 2011; Khan
et al. 2011; Law et al. 2006), coagulation (Huntington
2011; Khan et al. 2011; Law et al. 2006), fibrinolysis
(Huntington 2011; Khan et al. 2011), complement sys-
tem (Khan et al. 2011), apoptosis (Law et al. 2006), and
blood pressure (Ricagno et al. 2010). In the clinic, ser-
pins could also serve as biomarkers in the diagnosis and
therapy of cancer (Ghazy et al. 2011; Lim et al. 2012).
These potential markers include SERPINB11 (Lim et
al. 2012) and maspin - a non-inhibitory serpin which
is involved in apoptosis and reduces risk of metastasis
(Ghazy et al. 2011). This diverse array of functions is
Serpins: form, function, and dysfunction 52
down to the unique biochemistry of serpins.
Table 1. The Human Serpins
Serpin namea Target protease
(if inhibitory)
Function (if non-
inhibitory)
Official gene sym-
bol
Chromosomal loca-
tion
Source
Alpha-1-
antitrypsin
Elastase, plasmin,
thrombin, trypsin,
chymotrypsin,
and plasminogen
activator
SERPINA1 14q32.1 NCBI, Gene ID:
5265 (2013)
Alpha-1-
antitrypsin-like
Pseudogene SERPINA2 14q32.1 Seiksas et al.
(2006)
Alpha-1-
antichymotrypsin
Chymotrypsin SERPINA3 14q32.1 NCBI, Gene ID: 12
(2013); Rubin et al.
(1990)
Kallistatin Kallikrein SERPINA4 14q32.13 Chai et al. (1993);
NCBI, Gene ID:
5267 (2013)
Protein C inhibitor Protein C,
kallikreins, var-
ious plasminogen
activators
SERPINA5 14q32.1 NCBI, Gene ID:
5104 (2013)
Corticosteroid
binding globulin
Binds corticos-
teroid hormones
SERPINA6 14q32.1 NCBI, Gene ID:
866 (2013)
Thyroxine-binding
globulin
Binds thyroxine SERPINA7 Xq22.2 NCBI, Gene ID:
6906 (2013)
Angiotensinogen Precursor of an-
giotensin I
SERPINA8 1q42.2 NCBI, Gene ID:
183 (2013)
Germinal center
B-cell expressed
transcript-1
Trypsin, thrombin,
plasmin
SERPINA9 14q32.13 NCBI, Gene ID:
327657 (2013); Pa-
terson et al. (2007)
Protein-Z related
protease inhibitor
Factor Xa, Factor
XIa
SERPINA10 14q32.13 NCBI, Gene ID:
51156 (2013)
Serpin pepti-
dase inhibitor,
clade A (alpha-1
antiproteinase, an-
titrypsin), member
11
Serine-type en-
dopeptidases
SERPINA11 14q32.13 NCBI, Gene ID:
256394 (2013);
Nextprot BETA
(2013)
Vaspin Insulin-sensitising
adipocytokine
SERPINA12 14q32.13 Hida et al. (2005);
NCBI, Gene ID:
145264 (2013)
Serpin pepti-
dase inhibitor,
clade A (alpha-1
antiproteinase, an-
titrypsin), member
13
Pseudogene SERPINA13 14q32.13 NCBI, Gene ID:
388007 (2013)
Monocyte neu-
trophil elastase
inhibitor
Neutrophil elas-
tase, cathepsin G,
and proteinase-3
SERPINB1 6p5 NCBI, Gene ID:
1992 (2013)
Plasminogen acti-
vator inhibitor-2
Urinary plasmino-
gen activator,
tissue-type plas-
minogen activator
SERPINB2 18q21.3 Harrop et al.
(1999); NCBI,
Gene ID: 5055
(2013)
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Squamous cell car-
cinoma antigen-1
Cathepsin K,
cathepsin L,
cathepsin S
SERPINB3 18q21.3 NCBI, Gene ID:
6317 (2013); Schick
et al. (1998)
Squamous cell car-
cinoma antigen-2
Cathepin G, mast
cell chymase
SERPINB4 18q21.3 NCBI, Gene ID:
6318 (2013); Schick
et al. (1998)
Maspin Tissue-type plas-
minogen activator
SERPINB5 18q21.33 NCBI, Gene ID:
5268 (2013); Sheng
et al. (1998)
PI6 Cathepsin G SERPINB6 6p25 NCBI, Gene ID:
5269 (2013); Scott
et al. (1999);
Megsin Plasmin, matrix
metalloproteinases
SERPINB7 18q21.33 NCBI, Gene ID:
8710 (2013);
Ohtomo et al.
(2008);
PI8 Furin SERPINB8 18q21.1 Leblond et al.
(2006); NCBI,
Gene ID: 5271
(2013)
PI9 Granzyme B SERPINB9 6p25 NCBI, Gene ID:
5272 (2013)
Bomapin Thrombin, trypsin SERPINB10 18q21.3 NCBI, Gene ID:
5273 (2013);
Riewald and
Schleef (1995)
Serpin peptidase
inhibitor, clade
B (ovalbumin),
member 11
Unclear function
in host-pathogen
interactions
SERPINB11 18q21 cluster NCBI, Gene ID:
89778 (2013);
Seixas et al. (2012)
Yukopin Trypsin, plasmin SERPINB12 18q21 cluster Askew et al.
(2001); NCBI,
Gene ID: 89777
(2013)
Headpin Cathepsin L,
cathepsin V
SERPINB13 18q21.33 NCBI, Gene ID:
5275 (2013); Welss
et al. (2003)
Antithrombin Thrombin, factor
Xa, chymotrypsin
SERPINC1 1q25.1 NCBI, Gene ID:
462 (2013); Yang et
al. (2010)
Heparin cofactor II Thrombin SERPIND1 22q11.21 NCBI, Gene ID:
3053 (2013)
Plasminogen acti-
vator inhibitor type
1
Urinary plasmino-
gen activator,
tissue-type plas-
minogen activator
SERPINE1 7q22.1 NCBI, Gene ID:
5054 (2013)
Protease nexin-1 Thrombin SERPINE2 2q36.1 Li et al. (2012);
NCBI, Gene ID:
5270 (2013)
Pigment epithe-
lium derived factor
Neurotrophic
factor
SERPINF1 17p13.3 NCBI, Gene ID:
5176 (2013)
Alpha-2 antiplas-
min
Plasmin SERPINF2 17p13 NCBI, Gene ID:
5345 (2013)
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Complement-1 in-
hibitor
Activated C1r, ac-
tivated C1s
SERPING1 11q12.1 NCBI, Gene ID:
710 (2013)
Heat shock protein
47
Chaperone protein SERPINH1 11q13.5 NCBI, Gene ID:
871 (2013)
Neuroserpin Tissue-type plas-
minogen activator
SERPINI1 3q26.1 NCBI, Gene ID:
5274 (2013)
Pancpin Tissue-type plas-
minogen activator
SERPINI2 3q26.1 NCBI, Gene ID:
5276 (2013); Silver-
man et al. (2001)
aSerpin name is shaded if it is a known protease inhibitor
Figure 1: Serpin (AAT) and serine protease (trypsin) interaction
The trap is set (top)
The serpin (green) presents the RCL (yellow) containing the P1
residue (white) for its serine protease target (magenta). The ac-
tive site serine is white. The 4-stranded β-sheet A in red is a
metastable 2◦ structure.
The serine protease takes the bait (bottom)
After cleavage of the RCL the protease is covalently bound via its
reactive serine residue to the serpin (white). The RCL (yellow)
now inserts into β-sheet A to form a highly stable conformation.
The serine protease is irreversibly inhibited. The cleaved serpin
has a new chain (cyan). Note that the serine protease has been
dragged over 70, A˚ from the original position of the bait residue
to the serpin’s distal end.
Source: Pymol rendering using PDB entry 1K9O from Ye et al.,
(2001) (top) and PDB entry 1EZX from Huntington (2000) (bot-
tom)
1.2 Serpin Structure and Conforma-
tional Changes
Serpins are approximately 350− 400 amino acids long
(Patson 2000) and with a relative molecular weight
roughly 40 − 60 kDa (Gettins, 2002). They are glob-
ular (Ricagno et al. 2010) glycoproteins in their native
conformation (Hopkins et al. 1997). Their secondary
structure consists of helical (N-terminal) and β-barrel
(C-terminal) domains (Huntington 2011). There are a
total of nine α-helices (Patschull et al. 2011) as well as
three β-sheets (Patschull et al. 2011).
Serpins also possess a reactive centre loop or RCL
(Huntington 2011), exposed for the initial interaction
with the protease to be inhibited (Lawrence et al. 1994).
This peptide chain can be between 20 − 24 residues in
length (Huntington 2011). In the case of inhibitory ser-
pins, the RCL is characterised by an electrically neu-
tral residue at position P14, separated from the N-
terminal end of the ’bait’ amino acid (P1) by 12 residues
(Lawrence et al. 1994). The specificity of the serpin-
protease reaction is heavily dependent on the RCL ,
making RCL sequences a target for molecular engineer-
ing (Bottomley and Stone, 1998) and a source of serpin
mutational dysfunctions (Yamasaki et al. 2010).
The mechanism of inhibitory serpins involves a signifi-
cant change in their structure (Huntington 2000) as well
as that of the target protease (Huntington 2011). This
change from native to inhibiting state is associated with
an increase in the stability of the serpin structure (Singh
and Jairajpuri, 2011). In the native metastable state,
the serpin has a 5 stranded β-sheet A and an exposed
RCL; in the hyperstable state (following serpin-protease
interaction), the RCL has been cleaved and becomes in-
serted in the β-sheet A as the new fourth strand (Figure
1).
Serpins can also take on the hyperstable inactive con-
formation without protease interaction. This mecha-
nism involves incorporating the RCL into β-sheet A of
the same serpin molecule following disruption of the in-
termolecular bonds between the first chain in β-sheet C
and the rest of the sheet (Na and Im, 2007). The like-
lihood of taking this ’latent’ form affects the serpin’s
half-life (Thompson et al. 2011).
Research by Seo et al. (2000) showed that the strain
associated with the metastable structure is not localised
to one structure of the serpin, but is more likely to
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be diffuse. They identified several surface hydropho-
bic regions on α-1-antitrypsin (AAT) as contributors
to this global tension. Other reasons include over-
clustered side-chains, thermodynamically unfavourable
polar-nonpolar non-covalent bonds, and surface cavities
(Im et al. 1999). However, Seo et al. (2000) point
out that there is little, if any, effect on serpin inhibitory
activity following stabilising mutations in regions of ten-
sion which are not vital to serpin mechanism and which
are not involved in conformational change. One residue
which seems central to conformational change in AAT
and other serpins is lysine 335 (Im and Yu, 2000), which
interacts with helix F (hF) and the loop between hF and
β-sheet A’s third strand (thFs3A) (Seo et al. 2000).
A study by Baek et al. (2007) introduced disulfide
bonds into AAT in order to investigate the conforma-
tional changes occurring in serpins during inhibition.
Their study showed that in order for RCL incorpora-
tion as the fourth strand of β-sheet A, hF and thFs3A
must be able to move away from the fifth strand. Krish-
nan et al. (2011) also studied AAT and confirmed that
there is dissociation of hF from β-sheet A. They identi-
fied other conformational changes in the serpin preced-
ing RCL incorporation, such as dissociation of strands 5
and 6 from the rest of β-sheet A, and disruption of the
intermolecular bonds between RCL and β-sheets B and
C.
1.3 Protease Conformational Change
Serpins have a profound effect on target serine pro-
teases, not only by inhibiting the active site but also
by distorting the structure of the protease (Huntington
2000).
Serpins and their targets interact in a 1 to 1 ratio,
forming an SDS-stable complex (Egelund et al. 1998).
The resistance of this complex to SDS is explained by
the covalent bond formed between serpin and protease
(O’Malley et al. 1997). This, coupled with the ratio
of interaction, has led to serpins being called ’suicide’
inhibitors (Lawrence et al. 1995).
The P1 − P1′ bond of the serpin RCL serves as
’bait’ for the attacking protease, P1′ being the amino
acid closer to the C-terminal end (O’Malley et al.
1997). The protease cleaves the bond to form an acyl-
intermediate with the serpin (Lawrence et al. 1995).
Normally, protease action is completed by hydrolysis of
the acyl-intermediate to form a tetrahedral intermedi-
ate which then disintegrates, resulting in separation of
the protease-product complex (Hedstrom 2002). How-
ever, the formation of the acyl-intermediate is followed
by rapid burying of the RCL into β-sheet A as the
new fourth strand (Lawrence et al. 1995). This pre-
vents hydrolysis either by preventing entry of water into
the active site (Lawrence et al. 1995) or by disturb-
ing the conformation of the active site (Dementiev et
al. 2006; Huntington 2011), or both (O’Malley et al.
1997). Thus, serpin-protease complexes are trapped in
an acyl-intermediate stage (Egelund et al. 1998).
The incorporation of the RCL into β-sheet A also
drags the attached protease over 70A˚ from the origi-
nal position of the bait residue to the distal end of the
serpin and results in close approximation between ser-
pin and protease (Huntington 2000) as shown in Figure
1. This could explain the disturbance of active site ge-
ometry (Stratikos et al. 1999).
The active site is not the only portion of the pro-
tease which is affected. Another study on AAT-trypsin
complex (Huntington 2000) showed that approximately
37% of the protease becomes disordered as a result of
the dragging force exerted on Ser195 (in the active site)
as the RCL is incorporated into β-sheet A. This action
also destroys a salt-bridge between Ile16 and Asp194 of
the protease, formed during zymogen activation (Hunt-
ington 2000). The distortion of serine protease struc-
ture has been proposed as another facet to the serpin-
inhibition mechanism (Huntington 2000), in view of the
fact that such disordered proteases are more prone to
proteolytic attack (Egelund et al. 2001) and decreased
stability (Kaslik et al. 1997).
The degree of serine protease distortion varies from
one serpin-protease complex to another, possibly depen-
dent on factors including RCL length, the presence of
protease ligands such as Ca2+, and particular charac-
teristics of serpin and protease loops such as location,
length, and sequence (Huntington 2011).
1.4 Serpin Modulation
The glycosaminoglycans heparin and heparin sulphate
are modulators of many serpins’ function, activating
most of the serpins involved in haemostasis (Hunting-
ton 2003). However, heparin can also inhibit serpins,
such as kallistatin (Chen et al. 2001).
The majority of glycosaminoglycan-modulated serpins
possess a sequence neighbouring or involving helix D
for interaction with the glycosaminoglycan; the same is
true of helix H for protein C inhibitor (PCI) (Rein et
al. 2011). The mechanism of activation often involves
heparin binding to the serpin and the target protease,
bringing them closer and facilitating serpin-protease in-
teraction. Complexes falling under this category include
those between PCI and thrombin or activated protein C
(Li et al. 2008); antithrombin and thrombin, fIXa or
fXa (Olson et al. 2010); glia-derived nexin and throm-
bin (Baker et al. 1980); heparin cofactor II (HCII) and
thrombin (Verhamme, 2012); as well as protein Z in-
hibitor (PZI) and fXa or fXIa (Huang et al. 2011). The
bridging effect of heparin on PZI enables it to inhibit
free factors Xa and XIa, whereas other activating cofac-
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tors such as lipid, Ca2+, and protein Z promote PZI’s
inactivation of membrane-bound factor Xa (Huang et
al. 2011).
Interestingly, the ’bridging effect’ that heparin has on
serpins could have therapeutic relevance in oncology. A
study by Higgins et al. (2010) showed that heparin
improves the inhibition of the papain-like cathepsin L
by squamous cell carcinoma antigen-1 and -2 (SCCA-
1, SCCA-2), both of which are serpins. This find is
interesting in that not only could it explain heparin’s
anti-metastatic properties, but it is also the first report
of heparin promoting serpin inhibition of cysteine pro-
tease (Higgins et al. 2010).
Glycosaminoglycans can also enhance serpin function
through allosteric alterations (Rein et al. 2011), such as
with antithrombin and HCII. Heparin and heparan sul-
phate cause allosteric activating changes in antithrom-
bin mostly through a mutual pentasaccharide sequence
(Olson et al. 2010). This allosteric change does not in-
crease antithrombin’s inhibition of thrombin but of fac-
tors IXa and Xa (Olson et al. 2010) as well as plasma
kallikrein (Olson and Bjo¨rk, 1991). Ca2+ also increases
antithrombin’s inhibition of factor IXa by allosterically
activating the latter (Bedsted et al. 2003).
HCII’s inhibition of thrombin is also enhanced by
heparin through allosteric modifications (Baglin et al.
2002). Similarly to heparin, dermatan sulphate is an-
other glycosaminoglycan that activates HCII through
bridging and allosteric activation mechanisms (Ver-
hamme et al. 2004).
Alternatively, allosteric modification of the target pro-
tease can enhance serpin action. For example, interac-
tion of thrombomodulin with thrombin causes the pro-
tease configuration to alter, providing a binding-site for
the serpin PCI (Yange et al. 2003).
Other modulators of serpin function include vit-
ronectin and cations. The serpin plasminogen activa-
tor inhibitor-1 (PAI-1) inhibits β-trypsin, tissue-type
(tPA) and urokinase-type (uPA) plasminogen activator
(Komissarov et al. 2007) hence playing a crucial role
in the regulation of fibrinolysis. The half-life of PAI-1
is normally 1− 2 hours, however this can be altered by
modulating factors like vitronectin and cations (Thomp-
son et al. 2011). Vitronectin alone can prolong PAI-1
half-life by approximately 1.5 times (Thompson et al.
2011), through binding of vitronectin’s somatomedin
B domain to α-helix F of PAI-1 (Komissarov et al.
2007). Cations such as Mg2+ and Ca2+ prolong half-life
slightly, whereas Cu2+ and Co2+ without vitronectin re-
duce half-life significantly but prolong it in the presence
of vitronectin (Thompson et al. 2011). Calcium can
also inhibit the activity of AAT [discussed below].
Serpin modulation can also occur at the level of the
nucleus. Serpinin, released from neuroendocrine cells
during exocytosis of dense core granules (DCGs), inter-
acts with extracellular receptors to increase transcrip-
tion of protease nexin-1 (PN-1) (Koshimizu et al. 2010).
PN-1 is a serpin which prevents the proteolysis of DCG
proteins in the Golgi complex, thus favouring the re-
placement of the exocytosed DCGs (Kim et al. 2006).
On the other hand, PAI-1 transcription is increased
by transforming growth factor (TGF)-β, a mechanism
which has been implicated in vascular disease associ-
ated with non-insulin dependent diabetes (Nakayama et
al. 2011). PAI-2 transcription is inhibited by heparin
(Pepe et al. 1997), which contrasts with the activation of
PAI-1 by heparin. Maspin can also be regulated through
the rate of its transcription, either inhibited, such as by
protease activated receptor-1 (Villares et al. 2011), or
activated, such as by nitric oxide (Khalkhali-Ellis et al.
2003).
2 ALPHA-1-ANTITRYPSIN
(AAT)
2.1 The relevance of AAT
AAT has often been studied as an archetype for the
structure, function, and dysfunction of the serpin super-
family (Baek et al. 2007; Ekeowa et al. 2010; Hunting-
ton 2000; Krishnan et al. 2011; Mushero et al. 2011;
Sengupta et al. 2009; Seo et al. 2000), thus emphasising
its importance in understanding serpins.
2.2 Structure and function
Plasma AAT is 394 residues long (Janciauskiene et al.
1998), with a relative molecular weight of 52 kDa (Dick-
ens et al. 2011).
AAT has three glycans and eight alpha-helices, the lat-
ter of which consist mostly of the most N-terminal 150
residues (Loebermann et al. 1984). AAT inhibits neu-
trophil elastase, and is produced mainly in the liver at a
rate of 2 g/day (Greene and McElvaney, 2010) but also
in other sites (Dickens and Lomas 2011), particularly the
lungs (van’t Wout et al. 2011). In the lungs, AAT pro-
duction is higher in pro-inflammatory macrophages than
in anti-inflammatory macrophages and immature den-
dritic cells: in all cases, lipopolysaccharide stimulates
an increase in AAT release (van’t Wout et al. 2011).
The main role of AAT is to limit the damage inflicted
by neutrophil elastase on tissues at sites of inflammation
(Dickens and Lomas, 2011).
The ’bait’ residue for elastase is methionine 358: in
fact, oxidation of methionine at this position can block
inhibitory function (Taggart et al. 2000). Replacement
of this residue with arginine can result in AAT inhibit-
ing thrombin, causing heparin-independent anticoagu-
lant activity and a subsequent bleeding disorder (Owen
et al. 1983).
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AAT not only prevents lung tissue damage by inhibit-
ing neutrophil elastase, but also by inhibiting lung en-
dothelial cell apoptosis (Petrarche et al. 2006). This
is an example of cross-class inhibition, since RCL-intact
AAT is internalised by endothelial cells to directly in-
hibit caspase-3, a cysteine protease involved in apop-
tosis (Petrarche et al. 2006). The Z-variant of AAT
[discussed below] also has direct caspase-3 inhibitory ac-
tivity (Greene et al. 2010).
Another serine protease inhibited by AAT is matrip-
tase, an enzyme which spans the plasma membrane and
whose catalytic activity is extracellular (Janciauskiene
et al. 2008). Given the role of matriptase in activating
prostatin which then modulates epithelial sodium chan-
nels, inhibition of matriptase by AAT offers therapeutic
potential for patients with cystic fibrosis (characterised
by a defect in sodium absorption) (Janciauskiene et al.
2008).
2.3 AAT fragments
Elastase cleaves AAT to release a C-terminal product
of 4kDA (Schulze et al. 1992), corresponding to residues
358−394 (Janciauskiene et al. 1998). Tryspin gives the
same product: AAT-trypsin complex is composed of two
peptides which can be separated by SDS-page, showing
that the C-terminal product is bound to the complex by
non-covalent forces (Boswell et al. 1983).
The cleaved form of AAT has been shown to increase
LDL capture, internalisation, and breakdown in HepG2
cells (Janciauskiene et al. 1997). The cellular response
is likely initiated through binding of the C-terminal frag-
ment of cleaved AAT (Janciauskiene et al. 1998). Since
AAT is an acute-phase protein, this observation could
provide an explanation for hypocholesterolemia succeed-
ing inflammation (Janciauskiene et al. 1997).
The 36 residue C-terminal segment of cleaved AAT
also confers chemoattractant properties to elastase-AAT
complex, and thus mediates inflammation in the ab-
sence of bacteria or complement activation (Banda et
al. 1988).
Another truncated form of AAT is SPAAT. SPAAT
(short peptide from AAT) is composed of the 44 most
C-terminal residues of AAT and can be found bound
to the extracellular matrix in humans (Niemann et al.
1997a). Here, it could serve a protective role from excess
tissue degradation since it is a competitive reversible in-
hibitor of neutrophil elastase (Niemann et al. 1997b).
This contrasts with the irreversible inhibition of elastase
by full-length AAT. SPAAT can also be cleaved to re-
lease an octapeptide sequence (Wright et al. 2000).
This octapeptide (MFLEAIPM), formed from residues
P8-P1 of AAT RCL, was shown to inhibit elastase in a
study by Wright et al. 2000. Further kinetic analysis
showed that this was uncompetitive inhibition through
non-covalent interactions, mostly attributable to the
four most N-terminal residues. The study showed that
the octapeptide can also form an acyl-enzyme interme-
diate with elastase, and the uncompetitive inhibition
is possibly through stabilisation of this intermediate.
Taken together, SPAAT and MFLEAIPM present a pos-
sible ’cascade’ of protease inhibition by AAT (Wright et
al. 2000).
2.4 Regulation of AAT
In the lungs, the activity of AAT can be regulated by
surfactant A, a normal component of lung secretions
(Sarker et al. 2011). Surfactant A has been shown
to bind to AAT to limit its inhibition of elastase in a
calcium-dependent manner, involving the carbohydrate
side-chains of one or both of the glycoproteins (Gorrini
et al. 2005).
Elastase directly promotes transcription of AAT
mRNA in monocytes and bronchoalveolar macrophages
(Perlmutter et al. 1988). This is the case even in indi-
viduals homozygous for the Z variant of the AAT gene;
elastase has no effect on AAT secretion however, result-
ing in intracellular accumulation of AAT in these pa-
tients (Perlmutter et al. 1988).
Cations can also modulate the inhibition of trypsin.
Inactive trypsin (in an AAT-trypsin complex) exists in
equilibrium with the active form: the equilibrium can
be shifted towards formation of the latter by stabilising
it with Ca2+ ions (Calugaru et al. 2001).
2.5 AAT in immunity and inflammation
As an acute-phase protein, AAT serum levels can be
used as a marker of inflammatory response (Ziakas et al.
2011). Elastase-AAT complex also corresponds with in-
flammatory activity: neutrophil degranulation releases
neutrophil elastase, which is then inhibited by AAT,
forming the complex. For this reason, elastase-AAT can
be used as an indirect indication of reperfusion injury
following kidney transplant (Zynek-Litwin et al. 2010)
or of decreased survival chances in cystic fibrosis pa-
tients colonised with Burkholderia cenocepacia (Downey
et al. 2007).
AAT dampens inflammation in islet cells and other
tissues (Kalis et al. 2010), possibly due to impairment
of nuclear factor-kappaB (NFκB) function (Churg et al.
2001; Kalis et al. 2010). The mechanism of AAT’s inter-
ference with NFκB is unclear: however, it is associated
with increased levels of inhibitor of NF-κB (IκB), not
due to AAT’s protease inhibitory function (Churg et al.
2001).
Interestingly, AAT has shown promise as an adjunct to
immunosuppressive therapy to prolong graft viability in
insulin-dependent diabetic patients who have received
an islet transplant (Lewis et al. 2005). AAT directly
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inhibits a mediator of β-cell apoptosis, the cysteine pro-
tease caspase-3 (Zhang et al. 2007). AAT can also pre-
vent TNF-αmediated apoptosis in islet β-cells (Zhang et
al. 2007), as well as inhibiting other pro-inflammatory
cytokines (Pott et al. 2009); the mechanisms remain
elusive.
2.6 AAT in vascular disease
The lungs are not the only sites susceptible to damage
by imbalance between elastase and AAT levels. Patients
with ruptured and unruptured cerebral aneurysms have
been shown to have a serum elastase to AAT ratio al-
most double that of controls, implicating skewed elas-
tase:AAT as a cause of vessel wall damage (Baker et al.
1995).
AAT can protect against vascular disease (through
its elastase inhibition function) when associated with
HDL (Ortiz-Mun˜oz et al. 2009). AAT complexed with
LDLs (AAT-LDL) could also protect against vascular
disease, in women without metabolic syndrome (Kotani
et al. 2010). However, oxidative stress due to smoking
increases AAT-LDL levels, suggesting that AAT-LDL
might have a role to play in cardiovascular disease asso-
ciated with smoking (Wada et al. 2012).
2.7 AAT variants
Over 95% of AAT deficient individuals are homozy-
gous or heterozygous for the Z-allele (Greene and McEl-
vaney, 2010) on chromosome 14 (Elzouki 1999). The
Z-variant of AAT (ZAAT) is characterised by a replace-
ment of Glu342 with Lys (Lomas et al. 1995). ZAAT is
not secreted efficiently, hence the AAT deficiency: ho-
mozygotes (PiZZ) for the mutant allele have 15 − 20%
of normal circulating AAT levels (Elzouki, 1999). Thus,
PiZZ is characterised by emphysema (due to circulat-
ing AAT deficiency) and chronic liver disease (due to
inclusion of ZAAT in hepatocyte endoplasmic reticu-
lum) (Elzouki 1999). The hepatic inclusion bodies are
periodic acid-Schiff diastase (PASD)-resistant positive
(Francalanci et al. 2009) since ZAAT is a glycoprotein.
The buildup of ZAAT in endoplasmic reticulum (ER)
causes ER stress and deranged function (Greene et al.
2010). The accumulation of ZAAT is associated with
its ability to form polymers: in fact, reduced polymeri-
sation results in increased circulating ZAAT (Parfrey et
al. 2003).
ZAAT polymerises by a mechanism known as loop-
A-sheet polymerisation (refer to Figure 2), whereby the
RCL of one ZAAT molecule is inserted into the β-sheet
A of another ZAAT (Wilczynska et al. 2003). ZAAT
loop-sheet polymerisation is due to abnormal opening
of β-sheet A: a mutation of phenylalanine (position 51,
within the hydrophobic core) to leucine was shown to
inhibit β-sheet A opening, thus interfering with forma-
Figure 2: Hypothetical serpin polymerisation schemes
Top: Illustrates loop-A-sheet serpin (AAT) polymerisation. One
way that serpin subunits might form a polymeric structure is by
inserting the RCL as a fifth b-strand into a neighbouring sub-
unit’s β-sheet, in a loop-A-sheet polymerisation mechanism. The
distances and links between subunits is exaggerated for clarity. It
is envisaged that the close proximity of the β sheets in a serpin
polymer would encourage the formation of amyloid-like interac-
tions between subunits.
Bottom: Recent discoveries of dimers and trimers of the serpin
antithrombin III suggest a novel interaction through domain swap-
ping, whereby two β-strands are contributed by one subunit to a
neighbouring subunit’s β-sheet. Two complete subunits are shown
(green and red) while only the β-strand contribution is shown of
a third (blue). Continuation of the polymer would involve more
subunits using similar interactions.
Source: Pymol rendering using PDB entry 1EZX from Huntington
(2000) (top) and PDB entry 3T1P, Yamasaki et al. unpublished.
tion of ZAAT aggregates (Kim et al. 1995).
As mentioned previously, there are many sites on a ser-
pin which reduce the stability of its native state. One
AAT residue which marks such a site (a hydrophobic
surface cavity) is glycine 117 (Lee et al. 2000). This
pocket - formed by helix D, helix E, and β-sheet A
strand 2 - is obliterated in polymerisation of AAT (El-
liott et al. 2000). However, it can be ’filled’ by replac-
ing glycine 117 with phenylalanine (bulky side-chain)
to increase the stability of native AAT and limit poly-
merisation without eliminating AAT’s inhibitory action
(Parfrey et al. 2003). Similar results were observed in
ZAAT, where filling the pocket by replacing threonine
114 with phenylalanine resulted in decreased polymeri-
sation and increased ZAAT extracellular release (Par-
frey et al. 2003).
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Elliott et al. (2000) also studied the Gly117 cavity
as well as another four cavities, and compared the sizes
of these cavities between four serpins (AAT, alpha-1-
antichymotrypsin, PAI-1, and antithrombin). The de-
sign of small drugs which can occupy pockets such as
these without inhibiting serpin function can have an im-
portant role in limiting the pathological conditions as-
sociated with intracellular accumulation of polymerised
AAT and other serpins (Patschull et al. 2011; Elliott et
al. 2000).
Another variant of AAT which exhibits loop-A-sheet
polymerisation and accumulation in the endoplasmic
reticulum is Siiyama (S53F) (Lomas et al. 1995). The
Siiyama variant of AAT (SAAT) is prone to polymeri-
sation due to a propensity for opening of β-sheet A, and
impedance of its polymerisation results in increased se-
cretion (Sidhar et al. 1995). Also similar to ZAAT, this
variant results in hepatic disease and deficient serum
AAT (Janciauskiene et al. 2004).
Siiyama and ZAAT are the most frequent mutant
forms of AAT, and result in AAT deficiency in individu-
als homozygous for the alleles (PiSS and PiZZ genotypes
respectively) or possessing both alleles (PiSZ genotype)
(Ringenbach et al. 2011). Other variants exist though,
such as Mmalton, in which there is deletion of Phe52
(Curiel et al. 1989). Its frequency even exceeds that
of SAAT and ZAAT alleles in parts of the Southern
Mediterranean (Denden et al. 2010). Like SAAT and
ZAAT, Mmalton results in AAT deficiency and poly-
merises to form hepatic inclusions (Francalanci et al.
2009). However, plasma short-chain polymers of Mmal-
ton were found to be formed by insertion of RCL of one
Mmalton molecule into the β-sheet C of another (Lo-
mas et al. 1995). The exposed C-termini of these poly-
mers are more likely to attack by proteases, possibly
explaining why Mmalton extracted from blood contains
RCL-cleaved AAT (Yamasaki et al. 2011)
3 Serpin polymerisation
The loop-C-sheet polymerisation described above for
Mmalton can also be observed in C1 inhibitor (Elder-
ing et al. 1995) and antithrombin dimers (Carrell et al.
1994). In the case of antithrombin dimers, one molecule
(in the latent form) has the first strand of β-sheet C
separated from the rest of the sheet to permit inser-
tion of the other molecule’s RCL (Devlin and Bottomley,
2005). Loop-C-sheet polymers have also been observed
in in vitro studies on typical AAT and antithrombin
when heated with citrate (Devlin and Bottomley, 2005).
Zhang et al. (2008) propose that loop-C-sheet interac-
tions could also account for the polymerisation of the la-
tent forms of some serpins. Their crystallography study
of the latent form of tengpinDelta42 (a bacterial ser-
pin) showed hyperinsertion of the RCL into β-sheet A,
causing full exposure of β-sheet C. This then allows for
hydrogen-bonding between the exposed part of the RCL
of one latent serpin molecule with the second strand of
β-sheet C of another (Zhang et al. 2008).
Loop-A-sheet polymerisation occurs in AAT, neu-
roserpins (Santangelo et al. 2012), and α-1-
antichymotrypsin (Crowther et al. 2003). Tsutsui et al.
(2008) - using wild-type AAT as a paradigm for other
serpins - proposed that the mechanism of loop-A-sheet
polymerisation begins by disruption of β-sheet C. This
then leads to movement of the first strand from the rest
of the sheet via serpin-serpin interaction, causing con-
formational changes. One such change is the opening
of β-sheet A, which allows insertion of another serpin
molecule’s RCL into the sheet for polymerisation to oc-
cur (Tsutsui et al. 2008). Krishnan and Gierasch (2011)
point out that even under normal conditions, an equi-
librium exists between native serpin and an intermedi-
ate with an open β-sheet A. Although normally low in
concentration, this intermediate’s formation is increased
in certain AAT variants (e.g. ZAAT) due to a lower
thermodynamic barrier, explaining ZAAT’s tendency to
polymerise after release from hepatocytes (Krishnan et
al. 2011). However, the polymerisation of ZAAT and
other AAT mutants within hepatocytes is mostly due to
delayed folding to the native serpin state, giving inter-
mediates more opportunity chance to polymerise (Yu et
al. 1995).
’S7A’ polymerisation can be considered another loop-
sheet mechanism. The RCL of one molecule forms
hydrogen-bonds with the sixth strand of another
molecule’s β-sheet A, acting as a seventh strand (S7A)
(McGowan et al. 2006). Serpins which exhibit such
polymerisation include myeloid and erythroid nuclear
termination stage-specific protein (MENT) (McGowan
et al. 2006) and PAI-1 (Sharp et al. 1999). A mecha-
nism of ’S5A’ polymerisation was also proposed by Ya-
masaki et al. (2008), wherein both the RCL and the fifth
strand of the β-sheet A of one molecule are inserted into
the β-sheet A of the other. This mechanism might ex-
plain the highly chemically stable polymer which human
neuroserpin forms when incubated at 85◦C (Ricagno et
al. 2010).
Yamasaki et al. (2011) propose that polymerisation
via RCL insertion occurs via an intermediate which can
return to native state or form a polymer. If it is more
likely that the RCL is inserted into another molecule, a
polymer forms this intermediate state. However, RCL
insertion competes with the inclusion of the C-terminus
in the folded serpin, in which case the intermediate form
returns to native state. In fact, if the RCL insertion pro-
cess is slowed down, there is reduced polymerisation and
increased functional secretion in ZAAT (Yamasaki et al.
2010).
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The loop-sheet mechanisms are the best described
for serpin polymerisation, but they are not exclusive.
Marszal et al. (2003) described the polymerisation of
disulfide-linked dimers of wild-type AAT. The dimers
were obtained in vitro, using a mild denaturing buffer
without reducing agents, and polymerised through in-
termolecular interactions on the surface with β-sheet
A. The relevance of this find is unclear; however, the
similarity in structure (under the electron microscope)
of dimer polymers to loop-sheet polymers suggests that
the latter may involve disulfide bonds (Marszal et al.
2003).
Not all serpin multimers are pathological. For exam-
ple, S7a polymerisation of MENT could actually par-
ticipate in normal chromatin condensation (McGowan
et al. 2006). However, the vast majority of serpin poly-
mers are linked to disease states, such as those described
above for AAT variants.
Diseases may be due to deficiency of the serpin, which
is not secreted but is trapped as polymers in the en-
doplasmic reticulum (ER) of the secretory cell. This is
true for individuals homozygous for the mutant alleles of
AAT (as described above). Mutations of antithrombin,
α1-antichymotrypsin, and C1-inhibitor can also result in
intrahepatocyte polymer formation and subsequent de-
ficiency disease (Belorgey et al. 2007). Deficiency dis-
ease can also occur with spontaneous polymerisation fol-
lowing secretion, hence limiting the amount of available
serpin: for example, for individuals heterozygous and
homozygous for the F229L mutant allele of antithrom-
bin (Picard et al. 2003). Serpins need not necessarily
be mutant to polymerise and cause deficiency: wild-type
PAI-2 can undergo loop-sheet polymerisation within the
cytosol to eventually limit its own secretion (Mikus et
al. 1996).
Gain-of-function toxicity is another cause of disease.
One such case is that of mutant neuroserpin polymers
within ER, resulting in familial encephalopathy with
neuroserpin inclusion bodies (FENIB) (Miranda et al.
2008). One possible mediator of this disease is nuclear
factor kappa B (NF-κB), which is activated by the in-
traendoplasmic accumulation of neuroserpin polymers
(Davies et al. 2009). The pro-inflammatory mediator
NF-κB is also elevated with intraendoplasmic deposi-
tion of ZAAT polymers: inhibiting NF-κB’s actions (and
subsequent inflammation) may prove to be a line of ther-
apy for this genetic disease (Lawless et al. 2004).
Toxicity can also be a result of serpin oligomers, rather
than polymers. Carrell et al. (2008) used AAT and an-
tithrombin to demonstrate that in the initial stages of
serpin oligomer formation, the opening of the A-sheet
creates a β-acceptor site which can potentially bind to
physiologically significant peptides such as neurotrans-
mitters, resulting in toxicity. Hence, extension of the
oligomer to form a serpin auto-polymer is actually pro-
tective in that auto-polymerisation sequesters otherwise
toxic oligomers.
4 Conclusion
To conclude, although serpins’ roles in physiology and
disease are varied, they share a common structure which
allows great versatility and has proven to be an evo-
lutionary success. Understanding serpin structure and
their mechanism of inhibition is crucial to developing
treatments for their dysfunctions.
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